Back

Long-term outcomes associated with subcutaneous implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy

9 April 2024 (08:00 - 14:15)
Organised by: Logo
Congress Presentation Part of: Poster session on ventricular tachycardia, others Device Treatment EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Valeria Rella

Italian Auxological Institute San Luca Hospital, Milan (Italy)

105 More presentations in this session

Presentation thumbnail
Clinical accuracy of a 3-dimensional multielectrode non-invasive ECG mapping vest in premature ventricular contraction ablation procedures
Associate Professor B. Hunuk (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
Stereotactic arrhythmia radioablation for refractory ventricular tachycardia. A retrospective analysis and optimisation of the planning phase.
Mr J. Solana Munoz (Lausanne, CH)
Abstract
Presentation thumbnail
Electrophysiological characteristics of tachyarrhythmia and effects of catheter ablation in patients with Fontan circulation
Assistant Professor J. Uhm (Seoul, KR)
Abstract
Presentation thumbnail
Accuracy of pace-mapping using an automated template matching module for site of origin identification of idiopathic outflow tract premature ventricular contractions
Doctor N. Schaerli (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Epicardial catheter ablation of ventricular tachycardia in patients of acm - from a university hospital report in switzerland
Doctor F. Guan (Zurich, CH)
Abstract Slides Video

Access the full session

Session thumbnail
Poster session on ventricular tachycardia, others

The Event

Event poster

EHRA 2024

9 April 2024 08:00 CET
You may be interested in
thumbnail
Congress Session
Ventricular storm (2)
thumbnail
Congress Session
The storm will pass…
thumbnail
Congress Session
Ventricular tachycardia ablation in challenging scenarios: case-based management strategies

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources